Immunovative 
Welcome,         Profile    Billing    Logout  
 2 Products   7 Diseases   2 Products   2 Trials   66 News 


12»
  • ||||||||||  AlloStim (bioengineered allogeneic immune cells) / Immunovative
    Phase classification, Trial completion date, Trial primary completion date, Metastases:  STIMVAX: Immunotherapy for Third Line Metastatic Colorectal Cancer (clinicaltrials.gov) -  Mar 6, 2024   
    P2,  N=24, Recruiting, 
    Phase classification: P2b --> P2 | Trial completion date: Apr 2024 --> Apr 2025 | Trial primary completion date: Nov 2023 --> Nov 2024
  • ||||||||||  AlloStim (bioengineered allogeneic immune cells) / Immunovative
    Trial completion, Trial completion date:  ALLOPRIME: Universal Anti-Viral Vaccine for Healthy Elderly Adults (clinicaltrials.gov) -  Apr 18, 2023   
    P1/2,  N=40, Completed, 
    Phase classification: P2b --> P2 | Trial completion date: Apr 2024 --> Apr 2025 | Trial primary completion date: Nov 2023 --> Nov 2024 Recruiting --> Completed | Trial completion date: Dec 2023 --> Apr 2023
  • ||||||||||  AlloStim (bioengineered allogeneic immune cells) / Immunovative
    Trial completion date, Trial primary completion date, Metastases:  ALIVE: Immunotherapy for Advanced Liver Cancer (clinicaltrials.gov) -  Mar 2, 2023   
    P2/3,  N=150, Not yet recruiting, 
    Recruiting --> Completed | Trial completion date: Dec 2023 --> Apr 2023 Trial completion date: Feb 2025 --> Dec 2025 | Trial primary completion date: Aug 2024 --> Jun 2025
  • ||||||||||  AlloStim (bioengineered allogeneic immune cells) / Immunovative
    Trial completion date, Trial primary completion date, Metastases:  STIMVAX: Immunotherapy for Third Line Metastatic Colorectal Cancer (clinicaltrials.gov) -  Mar 1, 2023   
    P2b,  N=24, Recruiting, 
    Trial completion date: Feb 2025 --> Dec 2025 | Trial primary completion date: Aug 2024 --> Jun 2025 Trial completion date: Sep 2023 --> Apr 2024 | Trial primary completion date: Mar 2023 --> Nov 2023
  • ||||||||||  AlloStim (bioengineered allogeneic immune cells) / Immunovative
    Trial completion date, Trial primary completion date, Metastases:  STIMVAX: Immunotherapy for Third Line Metastatic Colorectal Cancer (clinicaltrials.gov) -  Aug 31, 2022   
    P2b,  N=24, Recruiting, 
    Trial completion date: Sep 2023 --> Apr 2024 | Trial primary completion date: Mar 2023 --> Nov 2023 Trial completion date: Feb 2023 --> Sep 2023 | Trial primary completion date: Sep 2022 --> Mar 2023
  • ||||||||||  AlloStim (bioengineered allogeneic immune cells) / Immunovative
    Trial completion date, Trial primary completion date:  ALLOPRIME: Universal Anti-Viral Vaccine for Healthy Elderly Adults (clinicaltrials.gov) -  Aug 31, 2022   
    P1/2,  N=40, Recruiting, 
    Trial completion date: Feb 2023 --> Sep 2023 | Trial primary completion date: Sep 2022 --> Mar 2023 Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Jun 2022 --> Mar 2023
  • ||||||||||  AlloStim (bioengineered allogeneic immune cells) / Immunovative
    New P2/3 trial, Metastases:  ALIVE: Immunotherapy for Advanced Liver Cancer (clinicaltrials.gov) -  Sep 1, 2021   
    P2/3,  N=150, Not yet recruiting, 
  • ||||||||||  AlloStim (bioengineered allogeneic immune cells) / Immunovative
    Enrollment open, Metastases:  STIMVAX: Immunotherapy for Third Line Metastatic Colorectal Cancer (clinicaltrials.gov) -  Jun 29, 2021   
    P2b,  N=24, Recruiting, 
    Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Jun 2022 --> Mar 2023 Not yet recruiting --> Recruiting
  • ||||||||||  AlloStim (bioengineered allogeneic immune cells) / Immunovative
    Enrollment open:  ALLOPRIME: Universal Anti-Viral Vaccine for Healthy Elderly Adults (clinicaltrials.gov) -  Jun 29, 2021   
    P1/2,  N=40, Recruiting, 
    Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
  • ||||||||||  AlloStim (bioengineered allogeneic immune cells) / Immunovative
    Trial initiation date, Trial primary completion date:  ALLOPRIME: Universal Anti-Viral Vaccine for Healthy Elderly Adults (clinicaltrials.gov) -  Jun 3, 2021   
    P1/2,  N=40, Not yet recruiting, 
    Not yet recruiting --> Recruiting Initiation date: Mar 2021 --> Jun 2021 | Trial primary completion date: Mar 2022 --> Jun 2022
  • ||||||||||  AlloStim (bioengineered allogeneic immune cells) / Immunovative
    Trial primary completion date, Metastases:  STIMVAX: Immunotherapy for Third Line Metastatic Colorectal Cancer (clinicaltrials.gov) -  Mar 16, 2021   
    P2b,  N=24, Not yet recruiting, 
    Initiation date: Mar 2021 --> Jun 2021 | Trial primary completion date: Mar 2022 --> Jun 2022 Trial primary completion date: Sep 2022 --> Dec 2022
  • ||||||||||  AlloStim (bioengineered allogeneic immune cells) / Immunovative
    Trial completion date, Trial primary completion date, Metastases:  STIMVAX: Immunotherapy for Third Line Metastatic Colorectal Cancer (clinicaltrials.gov) -  Jan 20, 2021   
    P2b,  N=24, Not yet recruiting, 
    Trial primary completion date: Sep 2022 --> Dec 2022 Trial completion date: Dec 2021 --> Mar 2023 | Trial primary completion date: Oct 2021 --> Sep 2022
  • ||||||||||  AlloStim (bioengineered allogeneic immune cells) / Immunovative
    Trial completion date, Trial primary completion date:  ALLOPRIME: Universal Anti-Viral Vaccine for Healthy Elderly Adults (clinicaltrials.gov) -  Jan 20, 2021   
    P1/2,  N=40, Not yet recruiting, 
    Trial completion date: Dec 2021 --> Mar 2023 | Trial primary completion date: Oct 2021 --> Sep 2022 Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Jul 2021 --> Mar 2022
  • ||||||||||  AlloStim (bioengineered allogeneic immune cells) / Immunovative
    Trial initiation date, Metastases:  STIMVAX: Immunotherapy for Third Line Metastatic Colorectal Cancer (clinicaltrials.gov) -  Nov 19, 2020   
    P2b,  N=24, Not yet recruiting, 
    Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Jul 2021 --> Mar 2022 Initiation date: Oct 2020 --> Jan 2021
  • ||||||||||  AlloStim (bioengineered allogeneic immune cells) / Immunovative
    Trial initiation date, Trial primary completion date:  ALLOPRIME: Universal Anti-Viral Vaccine for Healthy Elderly Adults (clinicaltrials.gov) -  Nov 19, 2020   
    P1/2,  N=40, Not yet recruiting, 
    Initiation date: Oct 2020 --> Jan 2021 Initiation date: Oct 2020 --> Jan 2021 | Trial primary completion date: Dec 2020 --> Jul 2021
  • ||||||||||  AlloStim (bioengineered allogeneic immune cells) / Immunovative, Hebrew University of Jerusalem, Hadassah Medical Organization
    [VIRTUAL] Novel allogeneic cell immunotherapy for advanced cancers (On-Demand e-Poster Display) -  Oct 8, 2020 - Abstract #ESMOAsia2020ESMO_Asia_1143;    
    Methods AlloStim®, was used on compassionate grounds AlloStim® is currently being evaluated in a phase IIB clinical trial in USA in MSI-S, chemotherapy-refractory, metastatic colorectal cancer patients, an indication known to present with “cold” lesions and to be non-responsive to ICI...Legal entity responsible for the study: Kananathan. Funding: Has not received any funding.
  • ||||||||||  AlloStim (bioengineered allogeneic immune cells) / Immunovative, Hebrew University of Jerusalem, Hadassah Medical Organization
    [VIRTUAL] Novel allogeneic cell immunotherapy for advanced cancers (On-Demand e-Poster Display) -  Oct 8, 2020 - Abstract #ESMOAsia2020ESMO_Asia_778;    
    AlloStim®, was used on compassionate grounds AlloStim® is currently being evaluated in a phase IIB clinical trial in USA in MSI-S, chemotherapy-refractory, metastatic colorectal cancer patients, an indication known to present with “cold” lesions and to be non-responsive to ICI...Simple to administer, minimal side-effects and appears to have activity in refractory metastatic disease. Further controlled clinical trials is warranted.
  • ||||||||||  AlloStim (bioengineered allogeneic immune cells) / Immunovative, Hebrew University of Jerusalem, Hadassah Medical Organization
    [VIRTUAL] Novel allogeneic cell immunotherapy for advanced cancers (On-Demand e-Poster Display) -  Oct 8, 2020 - Abstract #ESMOAsia2020ESMO_Asia_404;    
    AlloStim®, was used on compassionate grounds AlloStim® is currently being evaluated in a phase IIB clinical trial in USA in MSI-S, chemotherapy-refractory, metastatic colorectal cancer patients, an indication known to present with “cold” lesions and to be non-responsive to ICI...Simple to administer, minimal side-effects and appears to have activity in refractory metastatic disease. Further controlled clinical trials is warranted.
  • ||||||||||  AlloStim (bioengineered allogeneic immune cells) / Immunovative
    Trial initiation date, Trial primary completion date, Metastases:  STIMVAX: Immunotherapy for Third Line Metastatic Colorectal Cancer (clinicaltrials.gov) -  Aug 7, 2020   
    P2b,  N=24, Not yet recruiting, 
    Further controlled clinical trials is warranted. Initiation date: Jul 2020 --> Oct 2020 | Trial primary completion date: Jul 2021 --> Oct 2021
  • ||||||||||  AlloStim (bioengineered allogeneic immune cells) / Immunovative
    Trial initiation date:  ALLOPRIME: Universal Anti-Viral Vaccine for Healthy Elderly Adults (clinicaltrials.gov) -  Aug 7, 2020   
    P1/2,  N=40, Not yet recruiting, 
    Initiation date: Jul 2020 --> Oct 2020 | Trial primary completion date: Jul 2021 --> Oct 2021 Initiation date: Jul 2020 --> Oct 2020
  • ||||||||||  AlloVax (CRCL/AlloStim) / Immunovative
    Trial completion, Phase classification, Enrollment change, Metastases:  Safety and Tolerability Study of AlloVax(TM) in Patients With Metastatic or Recurrent Cancer of the Head and Neck (clinicaltrials.gov) -  Jan 23, 2020   
    P2,  N=12, Completed, 
    Allo-priming can be used as an adjuvant for anti-viral vaccines and as a counter-measure for unknown biological threats and bio-economic terrorism. Active, not recruiting --> Completed | Phase classification: P1/2 --> P2 | N=52 --> 12
  • ||||||||||  AlloVax (CRCL/AlloStim) / Immunovative
    Trial completion, Phase classification, Enrollment change, Trial completion date, Metastases:  An Individualized Anti-Cancer Vaccine in Advanced Hepatocellular Carcinoma Subjects (clinicaltrials.gov) -  Jan 22, 2020   
    P2a,  N=15, Completed, 
    N=25 --> 6 Recruiting --> Completed | Phase classification: P2 --> P2a | N=30 --> 15 | Trial completion date: Aug 2018 --> Mar 2019
  • ||||||||||  AlloStim (bioengineered allogeneic immune cells) / Immunovative
    Trial termination, Immune cell:  Bioengineered Allogeneic Immune Cells (AlloStim) Not Requiring HLA Donor Match for Blood Cancers (clinicaltrials.gov) -  Jan 22, 2020   
    P1/2,  N=2, Terminated, 
    Recruiting --> Completed | Phase classification: P2 --> P2a | N=30 --> 15 | Trial completion date: Aug 2018 --> Mar 2019 Withdrawn --> Terminated; withdrawn due to poor recruitment
  • ||||||||||  AlloStim (bioengineered allogeneic immune cells) / Immunovative
    Enrollment change, Trial withdrawal, Metastases:  AlloStim (clinicaltrials.gov) -  Jan 22, 2020   
    P2/3,  N=0, Withdrawn, 
    Withdrawn --> Terminated; withdrawn due to poor recruitment N=450 --> 0 | Not yet recruiting --> Withdrawn
  • ||||||||||  AlloStim (bioengineered allogeneic immune cells) / Immunovative
    Trial completion, Phase classification, Enrollment change, Combination therapy, Metastases:  AlloStim (clinicaltrials.gov) -  Jan 22, 2020   
    P2a,  N=12, Completed, 
    N=450 --> 0 | Not yet recruiting --> Withdrawn Recruiting --> Completed | Phase classification: P2 --> P2a | N=18 --> 12
  • ||||||||||  AlloVax (CRCL/AlloStim) / Immunovative
    Enrollment change, Trial withdrawal, Metastases:  Study Comparing AlloVax (clinicaltrials.gov) -  Jan 22, 2020   
    P2,  N=0, Withdrawn, 
    Withdrawn --> Completed N=100 --> 0 | Not yet recruiting --> Withdrawn
  • ||||||||||  AlloStim (bioengineered allogeneic immune cells) / Immunovative
    Enrollment open, Trial primary completion date, Combination therapy, Metastases:  AlloStim (clinicaltrials.gov) -  Oct 21, 2016   
    P2,  N=18, Recruiting, 
    N=100 --> 0 | Not yet recruiting --> Withdrawn Not yet recruiting --> Recruiting | Trial primary completion date: May 2018 --> Oct 2017
  • ||||||||||  AlloStim (bioengineered allogeneic immune cells) / Immunovative
    Trial initiation date, Trial primary completion date, Metastases:  AlloStim (clinicaltrials.gov) -  Aug 10, 2016   
    P2/3,  N=450, Not yet recruiting, 
    Not yet recruiting --> Recruiting | Trial primary completion date: May 2018 --> Oct 2017 Initiation date: Dec 2016 --> Dec 2017 | Trial primary completion date: Dec 2018 --> Dec 2019
  • ||||||||||  AlloVax (CRCL/AlloStim) / Immunovative
    Trial initiation date, Trial primary completion date, Metastases:  Study Comparing AlloVax (clinicaltrials.gov) -  Jul 19, 2016   
    P2,  N=100, Not yet recruiting, 
    Trial primary completion date: Jul 2016 --> Dec 2016 Initiation date: Jul 2016 --> Dec 2016 | Trial primary completion date: Jul 2018 --> Dec 2018
  • ||||||||||  AlloStim (bioengineered allogeneic immune cells) / Immunovative
    Trial initiation date, Combination therapy, Metastases:  AlloStim (clinicaltrials.gov) -  Jul 19, 2016   
    P2,  N=18, Not yet recruiting, 
    Initiation date: Jul 2016 --> Dec 2016 | Trial primary completion date: Jul 2018 --> Dec 2018 Initiation date: Jun 2016 --> Sep 2016
  • ||||||||||  AlloStim (bioengineered allogeneic immune cells) / Immunovative
    Trial initiation date, Trial primary completion date, Metastases:  AlloStim (clinicaltrials.gov) -  Apr 7, 2016   
    P2/3,  N=450, Not yet recruiting, 
    Not yet recruiting --> Recruiting Initiation date: Mar 2016 --> Dec 2016 | Trial primary completion date: Mar 2019 --> Dec 2018
  • ||||||||||  AlloStim (bioengineered allogeneic immune cells) / Immunovative
    Phase classification, Combination therapy, Metastases:  AlloStim (clinicaltrials.gov) -  Apr 6, 2016   
    P2,  N=18, Not yet recruiting, 
    Initiation date: Mar 2016 --> Dec 2016 | Trial primary completion date: Mar 2019 --> Dec 2018 Phase classification: P2b --> P2
  • ||||||||||  AlloVax (CRCL/AlloStim) / Immunovative
    Trial initiation date, Trial primary completion date, Metastases:  An Individualized Anti-Cancer Vaccine in Advanced Hepatocellular Carcinoma Subjects (clinicaltrials.gov) -  Feb 24, 2016   
    P2,  N=30, Not yet recruiting, 
    Phase classification: P2b --> P2 Initiation date: Nov 2015 --> Apr 2016 | Trial primary completion date: Nov 2016 --> Mar 2017
  • ||||||||||  AlloVax (CRCL/AlloStim) / Immunovative
    Trial initiation date, Trial primary completion date, Metastases:  Study Comparing AlloVax (clinicaltrials.gov) -  Feb 24, 2016   
    P2,  N=100, Not yet recruiting, 
    Initiation date: Nov 2015 --> Apr 2016 | Trial primary completion date: Nov 2016 --> Mar 2017 Initiation date: Mar 2016 --> Jul 2016 | Trial primary completion date: Mar 2018 --> Jul 2018
  • ||||||||||  AlloVax (CRCL/AlloStim) / Immunovative
    New P2 trial, Metastases:  Study Comparing AlloVax (clinicaltrials.gov) -  Dec 10, 2015   
    P2,  N=100, Not yet recruiting, 
  • ||||||||||  AlloStim (bioengineered allogeneic immune cells) / Immunovative
    Trial initiation date, Trial primary completion date, Combination therapy, Metastases:  AlloStim (clinicaltrials.gov) -  Aug 27, 2015   
    P2b,  N=18, Not yet recruiting, 
    Initiation date: Mar 2016 --> Jul 2016 | Trial primary completion date: Mar 2018 --> Jul 2018 Initiation date: Sep 2015 --> Jan 2016 | Trial primary completion date: Dec 2016 --> Dec 2017
  • ||||||||||  AlloStim (bioengineered allogeneic immune cells) / Immunovative
    Trial initiation date, Trial primary completion date, Metastases:  AlloStim (clinicaltrials.gov) -  Aug 27, 2015   
    P2/3,  N=450, Not yet recruiting, 
    Initiation date: Sep 2015 --> Jan 2016 | Trial primary completion date: Dec 2016 --> Dec 2017 Initiation date: Jan 2014 --> Jan 2016 | Trial primary completion date: Jan 2016 --> Jan 2019
  • ||||||||||  AlloVax (CRCL/AlloStim) / Immunovative
    Trial initiation date, Trial primary completion date, Metastases:  An Individualized Anti-Cancer Vaccine in Advanced Hepatocellular Carcinoma Subjects (clinicaltrials.gov) -  Aug 14, 2015   
    P2,  N=30, Not yet recruiting, 
    Enrolling by invitation --> Active, not recruiting | Trial primary completion date: Jul 2015 --> Jul 2016 Initiation date: Jun 2015 --> Oct 2015 | Trial primary completion date: Jun 2016 --> Oct 2016
  • ||||||||||  AlloStim (bioengineered allogeneic immune cells) / Immunovative
    Enrollment change, Trial withdrawal, Combination therapy:  In-Situ Therapeutic Cancer Vaccine for Refractory Liver Cancer (clinicaltrials.gov) -  Apr 15, 2015   
    P1/2,  N=0, Withdrawn, 
    Initiation date: Jun 2015 --> Oct 2015 | Trial primary completion date: Jun 2016 --> Oct 2016 N=10 --> 0 | Not yet recruiting --> Withdrawn
  • ||||||||||  AlloVax (CRCL/AlloStim) / Immunovative
    Enrollment change, Trial withdrawal:  An Individualized Anti-Cancer Vaccine Study in Patients With HCC (clinicaltrials.gov) -  Apr 14, 2015   
    P1/2,  N=0, Withdrawn, 
    N=31 --> 0 | Not yet recruiting --> Withdrawn N=200 --> 0 | Not yet recruiting --> Withdrawn
  • ||||||||||  AlloStim (bioengineered allogeneic immune cells) / Immunovative
    Enrollment change, Trial withdrawal, Metastases:  AlloStim (clinicaltrials.gov) -  Apr 14, 2015   
    P2/3,  N=0, Withdrawn, 
    N=200 --> 0 | Not yet recruiting --> Withdrawn N=208 --> 0 | Not yet recruiting --> Withdrawn